Nektar's immunology drug misses in Phase 2b, execs cite enrollment errors

AgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.st

BioPharma DiveTango data add to growing momentum for pancreatic cancer drugs

Thermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab Products

BioPharma DiveIncyte to buy blood disorder drug in possibly $2B deal

FierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse merger

FierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patients

BioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

Endpoints NewsTreeline to go public via reverse merger with Standard BioTools

Roche MediaThis Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug - Barron's

BioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

FierceBiotechResmed snaps up Noctrix Health in $340M sleep tech deal

BioWorldBiggest gainers and losers for June 1-5, 2026